New CMV prevention drug could be safer for kidney transplant patients
NCT ID NCT07266467
First seen Jan 09, 2026 · Last updated Jun 19, 2026 · Updated 26 times
Summary
This study compares a new drug called leymovir to the standard drug valganciclovir for preventing cytomegalovirus (CMV) infection in 290 Chinese kidney transplant recipients. Leymovir targets a different part of the virus, which may reduce side effects like bone marrow suppression and kidney damage. The goal is to see if leymovir is as effective and safer than the current treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY TRANSPLANT are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Xi 'an Jiaotong University
RECRUITINGXi'an, Shaanxi, 710000, China
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Letermovir
What this could lead to
If successful, leymovir could offer a safer alternative to current CMV drugs, with fewer side effects like low white blood cell counts and less kidney strain.
What could go wrong
This is a phase 4 trial focused on Chinese patients, so results may not apply to other populations. The drug may still cause unexpected side effects or prove less effective than hoped.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.